Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMA: ProHema-CB in Hematologic Malignancies
NCT01627314Phase 2Terminated
- Sponsor
- Fate Therapeutics
- Start
- Jul 2012
- Primary completion
- Mar 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ProHema in acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), sponsored by Fate Therapeutics. Started Jul 2012; status: terminated.
02
Drugs
ProHema
03
Conditions
acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01627314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01627314.